Liver Transplantation for Hepatocellular Carcinoma: A Single Center Resume Overlooking Four Decades of Experience

Figure 1

Annual proportions of underlying diseases (a), neoadjuvant therapies (b), UICC-7 staging (c), and tumor morphologies (d). (a) There was no significant change in annual proportions of recipients underlying diseases over time. (b) Tumor morphologies of transplanted HCC changed over time in the favour of uninodular and unilateral tumors. (c) The overall rate for neoadjuvant therapy as well as the diversity of different treatment combinations increased over time. This effect was caused due to new therapies that were introduced consecutively from 1975 to 2010 (surgery (S), chemotherapy (CTX), transarterial chemoembolisation (TACE), percutaneous ethanol instillation (PEI), selective internal radiation therapy (SIRT), and monoclonal antibodies (mAB)). (d) Between 1975 and 2010 the proportion of low graded UICC-7 staged tumors increased significantly.

(a)

(b)

(c)

(d)